公开(公告)号：EP3589649A1

公开(公告)日：2020-01-08

申请号：EP18710971.5

申请日：2018-02-27

申请人： The Trustees of The University of Pennsylvania ,  Janssen Biotech, Inc.

发明人： LIMBERIS, Maria P. ,  TRETIAKOVA, Anna P. ,  WILSON, James M. ,  NASO, Michael ,  KOLKMAN, Joost ,  FRIESEN, Robert ,  WANG, Qiang

IPC分类号： C07K16/10 ,  C12N7/00 ,  C12N15/86

公开(公告)号：EP3699286A1

公开(公告)日：2020-08-26

申请号：EP19212363.6

申请日：2012-04-20

申请人： The Trustees of the University of Pennsylvania

发明人： WILSON, James M. ,  LIMBERIS, Maria P.

IPC分类号： C12N15/861 ,  A61K39/40 ,  A61K39/42

摘要： A prophylactic regimen for passively preventing infection with a pathogen which has a typical route of infection through the nasopharynx region of a subject, e.g., an airborne virus typically transmitted through coughing or sneezing. The method involves specifically targeting a subject's nasopharynx with a viral vector comprising an AAV capsid and carrying a nucleic acid sequence encoding an anti-viral neutralizing antibody construct operably linked to expression control sequences, in order to provide for high levels of expression of the anti-viral neutralizing antibody construct in the nasal airway cells. Optionally, the neutralizing antibody construct is expressed under a promoter which is regulated or induced by a small molecule which is delivered separately from the viral vector. In one embodiment, the method permits transfection of a subject's nasopharynx even where the subject has circulating neutralizing antibodies against the AAV capsid.